Clinical trial
An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose Study to Evaluate the Effects of MK0736 on Atherosclerotic Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease
NCT00679055 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose Study to Evaluate the Effects of MK0736 on Atherosclerotic Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 31, 2007
- Completion date
- August 26, 2008
- Enrollment
- 14 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.